Search Results

Pharmaceutical Associates, Inc. (PAI) announces that it has acquired all of the generic and branded US marketing authorizations from Teligent Inc. (Teligent) for an undisclosed amount.

Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021.

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S.

Teligent, Inc. (Nasdaq: TLGT), (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors

Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the second quarter of 2021 and provided a business update.

Teligent, Inc. announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented.

Generic Pharmaceutical and Contract Manufacturing Industry Leader Joins Teligent Board, Effective Immediately

Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent’s Board of Directors, replacing James C. Gale who opted to not stand for reelection to Teligent’s board of directors in order to devote more time to other business interests. Mr. Celentano joined Tel

Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the first quarter of 2021 and provided a business update.

Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2020.